Luminex Confirms Effectiveness of xTAG® Respiratory Viral Panel for Swine Flu Surveillance
01 May 2009 - 3:28AM
Business Wire
Luminex Corporation (NASDAQ: LMNX), the worldwide leader in
multiplexed solutions, today issued a follow-up statement to an
announcement on Monday, April 27, 2009, confirming that the xTAG�
Respiratory Viral Panel (RVP) assay has been demonstrated to be
effective in surveillance of swine flu. Specifically, Luminex has
verified through testing on confirmed swine flu-positive samples
that the xTAG RVP assay will correctly identify these samples as
positive for influenza A and negative for common seasonal flu
strains of influenza A H1 and H3. This is the expected outcome for
novel influenza A strains which prompts follow-up testing by state
or federal public health labs with assays such as the Centers for
Disease Control (CDC) swine flu assay.
Over the past several days, scientists at Luminex have reviewed
data provided by public health laboratories in Canada and the
United States, and have internally generated data that indicate
that the xTAG RVP assay is effective in swine flu surveillance. As
a result of xTAG RVP�s unique ability to simultaneously identify
the influenza A virus matrix gene and specific common seasonal flu
subtypes of that virus, H1 and H3, xTAG RVP can be an effective
tool in a public health setting. In this environment, a test with
this capability could prove to be essential for an effective
surveillance program.
�xTAG RVP�s ability to determine if a patient is carrying a
normal, seasonal respiratory virus or an unknown H1 flu A virus can
be a critical first line of defense in separating standard
respiratory infections from swine flu cases,� said Patrick J.
Balthrop, Sr., president and chief executive officer of Luminex.
�Luminex is very pleased to have the opportunity to have a positive
impact in this surveillance effort. This is a critical situation,
and we are hopeful that xTAG RVP will be useful in protecting the
public health. Our investment in the research and development of
unique, innovative products such as xTAG RVP has been a top
priority for our company. We look forward to continuing to work
with public health officials and health care professionals,
including our customers, to deliver quality results and improve the
lives of people worldwide.�
xTAG RVP was cleared by the FDA in January 2008, and is the only
commercially-available test that can simultaneously detect 12
respiratory viruses and subtypes, including Flu A with subtyping,
at the DNA/RNA level. During an outbreak this test can provide the
physician with valuable information as most patients will be
positive for one of the more common viruses included in the panel.
In the event that a rare Flu A virus is detected, as included in
the xTAG RVP labeling and package insert reviewed and cleared by
FDA, samples that test positive for total Flu A but are not
positive for the included seasonal flu subtypes should be referred
to a public health lab such as CDC for follow up.
Luminex is continuing to work with many current customers,
including public health laboratories and officials to gather
additional data and samples to further confirm their findings.
xTAG RVP is available in the U.S. through Luminex Molecular
Diagnostics, Fisher HealthCare and Abbott Laboratories. It is
available worldwide from Luminex Molecular Diagnostics and
Abbott.
For more information on xTAG RVP, please visit
www.luminexcorp.com/rvp.
About Luminex Corporation
Luminex Corporation develops, manufactures and markets
proprietary biological testing technologies with applications
throughout the diagnostic and life sciences industries. The
Company�s xMAP� multiplex solutions include an open-architecture,
multi-analyte technology platform that delivers fast, accurate and
cost-effective bioassay results to markets as diverse as
pharmaceutical drug discovery, clinical diagnostics and biomedical
research, including the genomics and proteomics markets. The
Company�s xMAP Technology is sold worldwide and is already in use
in leading clinical laboratories as well as major pharmaceutical,
diagnostic and biotechnology companies. Further information on
Luminex Corporation or xMAP Technology can be obtained at
www.luminexcorp.com.
Statements made in this release that express Luminex�s or
management�s intentions, plans, beliefs, expectations or
predictions of future events are forward-looking statements. The
words �believe,� �expect,� �intend,� �estimate,� �anticipate,�
�will,� �could,� �should� and similar expressions are intended to
further identify such forward-looking statements for purposes of
the Private Securities Litigation Reform Act of 1995. It is
important to note that the Company�s actual results or performance
could differ materially from those anticipated or projected in such
forward-looking statements. Factors that could cause Luminex�s
actual results or performance to differ materially include risks
and uncertainties relating to, among others, market demand and
acceptance of Luminex�s products, the Company�s dependence on
strategic partners for development, commercialization and
distribution of products, concentration of the Company�s revenue in
a limited number of strategic partners, fluctuations in quarterly
results due to a lengthy and unpredictable sales cycle and bulk
purchases of consumables, Luminex�s ability to scale manufacturing
operations and manage operating expenses, gross margins and
inventory levels, potential shortages of components, competition,
the timing of regulatory approvals, the implementation, including
any modification, of the Company�s strategic operating plans, risks
and uncertainties associated with implementing our acquisition
strategy and the ability to integrate acquired companies or
selected assets into our consolidated business operations, as well
as the risks discussed under the heading �Risk Factors� in
Luminex�s Reports on Forms 10-K and 10-Q, as filed with the
Securities and Exchange Commission. The forward-looking statements
contained herein represent the judgment of Luminex as of the date
of this press release, and Luminex expressly disclaims any intent,
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements to reflect any change
in Luminex�s expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based.
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jul 2023 to Jul 2024